Overview

Phase I/II Study of Curdlan Sulfate

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single doses and then, after FDA review, daily doses for 7 days.

Phase:

Phase 1

Details

Lead Sponsor:

AJI Pharma USA

Treatments:

Curdlan sulfate